Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis
暂无分享,去创建一个
J. Farrar | M. Pirmohamed | A. Winston | S. Khoo | D. Carr | T. Solomon | D. Back | A. Ustianowski | M. Nelson | L. Else | T. Chau | M. Fisher | S. Nightingale | Steven Taylor | M. E. Törok
[1] C. Leen,et al. Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia , 2016, Journal of NeuroVirology.
[2] A. Telenti,et al. In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid , 2016, Drug Metabolism and Disposition.
[3] H. Jessen,et al. Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] A. Antunes,et al. The phenolic metabolites of the anti-HIV drug efavirenz: evidence for distinct reactivities upon oxidation with Frémy's salt. , 2014, European journal of medicinal chemistry.
[5] J. McArthur,et al. Dendritic Spine Injury Induced by the 8-Hydroxy Metabolite of Efavirenz , 2012, Journal of Pharmacology and Experimental Therapeutics.
[6] Namandjé N. Bumpus. Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and BimEL-dependent mechanism in primary human hepatocytes. , 2011, Toxicology and applied pharmacology.
[7] C. Hendrix,et al. The Male Genital Tract Is Not a Pharmacological Sanctuary From Efavirenz , 2011, Clinical pharmacology and therapeutics.
[8] J. Farrar,et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] Kwang-Hyeon Liu,et al. Rapid and Simultaneous Determination of Efavirenz, 8-Hydroxyefavirenz, and 8,14-Dihydroxyefavirenz Using LC–MS–MS in Human Plasma and Application to Pharmacokinetics in Healthy Volunteers , 2011 .
[10] A. Amara. Development and validation of a HPLC-MS/MS assay to quantify the anti-retroviral (ARV) drug, efavirenz and its major metabolites in plasma , 2011 .
[11] Y. Teo,et al. Genomic copy number variations in three Southeast Asian populations , 2010, Human mutation.
[12] L. Milani,et al. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. , 2009, British journal of clinical pharmacology.
[13] M. J. García,et al. Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus Patients , 2009, Antimicrobial Agents and Chemotherapy.
[14] A. Telenti,et al. Pharmacogenetics‐Based Population Pharmacokinetic Analysis of Efavirenz in HIV‐1‐Infected Individuals , 2009, Clinical pharmacology and therapeutics.
[15] Huldrych F. Günthard,et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function , 2009, Pharmacogenetics and genomics.
[16] Shuji Ohno,et al. Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction , 2009, Drug Metabolism and Disposition.
[17] J. Farrar,et al. Clinical and Microbiological Features of HIV-Associated Tuberculous Meningitis in Vietnamese Adults , 2008, PloS one.
[18] M Schwab,et al. Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV‐infected Individuals , 2007, Clinical pharmacology and therapeutics.
[19] A. Telenti,et al. Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents , 2006, Current HIV/AIDS reports.
[20] B. Stilwell,et al. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .
[21] S. Khoo,et al. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. , 2005, The Journal of antimicrobial chemotherapy.
[22] A. Tunkel. Dexamethasone for treatment of tuberculous meningitis in adolescents and adults , 2005, Current infectious disease reports.
[23] Amalio Telenti,et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients , 2005, Pharmacogenetics and genomics.
[24] Catia Marzolini,et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study , 2004, AIDS.
[25] S. Oka,et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. , 2004, Biochemical and biophysical research communications.
[26] A. Sönnerborg,et al. Efavirenz Plasma Concentrations in HIV-Infected Patients: Inter- and Intraindividual Variability and Clinical Effects , 2004, Therapeutic drug monitoring.
[27] R. Tyndale,et al. The Unique Regulation of Brain Cytochrome P450 2 (CYP2) Family Enzymes by Drugs and Genetics , 2004, Drug metabolism reviews.
[28] D. Mash,et al. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain , 2003, Neuropharmacology.
[29] David A. Flockhart,et al. The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.
[30] Jacques Fellay,et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection , 2003, Clinical pharmacology and therapeutics.
[31] J. Barrett,et al. Population pharmacokinetic meta-analysis with efavirenz. , 2002, International journal of clinical pharmacology and therapeutics.
[32] A. Telenti,et al. Efavirenz Plasma Levels Can Predict Treatment Failure and Central Nervous System Side Effects in Hiv-1-infected Patients , 2022 .
[33] M. Boyd,et al. Multiple forms of cytochrome P450 and associated monooxygenase activities in human brain mitochondria. , 2000, Biochemical pharmacology.
[34] T. Tephly,et al. Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate. , 1999, Archives of biochemistry and biophysics.
[35] K. Blennow,et al. Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. , 1993, European neurology.
[36] R. Bulger,et al. Antimicrobial Agents and Chemotherapy , 1969, Nature.